Gold prices cool after hitting over 2-week high on Fed independence fears
Investing.com -- Tempus AI , Inc. (NASDAQ:TEM), a precision medicine technology company, reported better-than-expected first quarter results and raised its full-year revenue guidance, though shares slipped 2.3% following the announcement.
The company posted adjusted earnings per share of -$0.24 for Q1 2025, surpassing analyst estimates of -$0.26. Revenue soared 75.4% YoY to $255.7 million, exceeding the consensus forecast of $248.5 million. Tempus attributed the strong performance to growth across its genomics and data services segments.
"The business is performing well with revenues growing, margins improving, and our costs remaining in check, allowing us to demonstrate significant year-over-year operating leverage," said Eric Lefkofsky, Founder and CEO of Tempus.
Tempus raised its full-year 2025 revenue guidance to $1.25 billion, representing approximately 80% growth YoY. The company also expects to achieve positive adjusted EBITDA of $5 million for the full year, an improvement of about $110 million over 2024.
Quarterly gross profit nearly doubled YoY to $155.2 million, with margins improving in both genomics and data services. The genomics segment contributed $193.8 million in revenue, up 88.9% YoY, while data and services revenue grew 43.2% to $61.9 million.
Tempus recently announced strategic collaborations with AstraZeneca (NASDAQ:AZN) and Pathos to develop a multimodal foundation model in oncology, which is expected to generate an additional $200 million in data licensing and model development fees over the next three years.
Despite the positive results and outlook, Tempus shares edged down 2.3% in after-hours trading, possibly due to high investor expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.